Skip to main navigation Skip to main content

Clin Mol Hepatol : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

4
results for

"Hyponatremia"

Article category

Keywords

Publication year

"Hyponatremia"

Correspondence

Artificial intelligence, epidemiology, methodology, or others

Correspondence on Letter regarding “Evidence-based hyponatremia management in liver disease”
Ji Young Ryu, Seon Ha Baek, Sejoong Kim
Clin Mol Hepatol 2023;29(4):1048-1049.
Published online August 14, 2023
DOI: https://doi.org/10.3350/cmh.2023.0261
Correction in: Clin Mol Hepatol 2024;30(1):134
  • 7,439 View
  • 49 Download

Review

Artificial intelligence, epidemiology, methodology, or others

Evidence-based hyponatremia management in liver disease
Ji Young Ryu, Seon Ha Baek, Sejoong Kim
Clin Mol Hepatol 2023;29(4):924-944.
Published online June 5, 2023
DOI: https://doi.org/10.3350/cmh.2023.0090
Hyponatremia is primarily a water balance disorder associated with high morbidity and mortality. The pathophysiological mechanisms behind hyponatremia are multifactorial, and diagnosing and treating this disorder remains challenging. In this review, the classification, pathogenesis, and step-by-step management approaches for hyponatremia in patients with liver disease are described based on recent evidence. We summarize the five sequential steps of the traditional diagnostic approach: 1) confirm true hypotonic hyponatremia, 2) assess the severity of hyponatremia symptoms, 3) measure urine osmolality, 4) classify hyponatremia based on the urine sodium concentration and extracellular fluid status, and 5) rule out any coexisting endocrine disorder and renal failure. Distinct treatment strategies for hyponatremia in liver disease should be applied according to the symptoms, duration, and etiology of disease. Symptomatic hyponatremia requires immediate correction with 3% saline. Asymptomatic chronic hyponatremia in liver disease is prevalent and treatment plans should be individualized based on diagnosis. Treatment options for correcting hyponatremia in advanced liver disease may include water restriction; hypokalemia correction; and administration of vasopressin antagonists, albumin, and 3% saline. Safety concerns for patients with liver disease include a higher risk of osmotic demyelination syndrome.

Citations

Citations to this article as recorded by  Crossref logo
  • High-dosage human albumin infusion may be superior for hypervolemic hyponatremia in cirrhosis with ascites
    Xianxian Zhang, Lu Chai, Haonan Zhao, Haitao Zhao, Ran Wang, Mauro Bernardi, Xingshun Qi
    Expert Review of Gastroenterology & Hepatology.2026; 20(3): 289.     CrossRef
  • Hyponatremia in Cirrhosis: Comparative Evaluation of MELD and MELD-Na Scores for Predicting Short- and Long-Term Mortality
    Goutami V. Kohir, Nagaraj Kotli
    APIK Journal of Internal Medicine.2026; 14(1): 37.     CrossRef
  • Management of Hyponatremia in Cirrhosis
    Justin M. Belcher
    Current Hepatology Reports.2026;[Epub]     CrossRef
  • Accurate urine sodium measurements at home using point of care testing in patients with short bowel syndrome
    Miranda Van Berkel, Judith Beurskens-Meijerink, Nicole Buters-Ambrosius, Eline Van Der Hagen, Getty Huisman- De Waal, Geert Wanten
    Clinical Nutrition ESPEN.2025; 66: 262.     CrossRef
  • Etiology, Clinical Approach, and Therapeutic Consequences of Hyponatremia
    Goce Spasovski
    Kidney and Dialysis.2024; 4(1): 37.     CrossRef
  • Association of baseline serum sodium with long-term outcomes in newly diagnosed coronary heart disease patients without heart failure: a prospective cohort study
    Zelong Cao, Wenqing Zhu, Chaonan Shen, Bo Gao, Naying Jin, Fang Li, Bin Zhang, Gang Liu, Liang Zheng, Mingqi Zheng
    Scientific Reports.2024;[Epub]     CrossRef
  • Hyponatraemia—treatment standard 2024
    Goce Spasovski
    Nephrology Dialysis Transplantation.2024; 39(10): 1583.     CrossRef
  • Correspondence on Letter regarding “Evidence-based hyponatremia management in liver disease”
    Ji Young Ryu, Seon Ha Baek, Sejoong Kim
    Clinical and Molecular Hepatology.2023; 29(4): 1048.     CrossRef
  • Letter regarding “Evidence-based hyponatremia management in liver disease”
    Daphne J. Theodorou, Stavroula J. Theodorou, Ioannis V. Mitselos
    Clinical and Molecular Hepatology.2023; 29(4): 1043.     CrossRef
  • Pulmonary Complications in Patients with Liver Cirrhosis
    Seul Ki Han, Soon Koo Baik, Moon Young Kim
    The Korean Journal of Gastroenterology.2023; 82(5): 213.     CrossRef
  • 14,130 View
  • 377 Download
  • 9 Web of Science
  • Crossref

Original Article

Liver fibrosis, cirrhosis, and portal hypertension

The refit model for end-stage liver disease-Na is not a better predictor of mortality than the refit model for end-stage liver disease in patients with cirrhosis and ascites
Jun Jae Kim, Jeong Han Kim, Ja Kyung Koo, Yun Jung Choi, Soon Young Ko, Won Hyeok Choe, So Young Kwon
Clin Mol Hepatol 2014;20(1):47-55.
Published online March 26, 2014
DOI: https://doi.org/10.3350/cmh.2014.20.1.47
Background/Aims

The modification of the Model for End-Stage Liver Disease (MELD) scoring system (Refit MELD) and the modification of MELD-Na (Refit MELDNa), which optimized the MELD coefficients, were published in 2011. We aimed to validate the superiority of the Refit MELDNa over the Refit MELD for the prediction of 3-month mortality in Korean patients with cirrhosis and ascites.

Methods

We reviewed the medical records of patients admitted with hepatic cirrhosis and ascites to the Konkuk University Hospital between January 2006 and December 2011. The Refit MELD and Refit MELDNa were compared using the predictive value of the 3-month mortality, as assessed by the Child-Pugh score.

Results

In total, 530 patients were enrolled, 87 of whom died within 3 months. Alcohol was the most common etiology of their cirrhosis (n=271, 51.1%), and the most common cause of death was variceal bleeding (n=20, 23%). The areas under the receiver operating curve (AUROCs) for the Child-Pugh, Refit MELD, and Refit MELDNa scores were 0.754, 0.791, and 0.764 respectively; the corresponding values when the analysis was performed only in patients with persistent ascites (n=115) were 0.725, 0.804, and 0.796, respectively. The significant difference found among the Child-Pugh, Refit MELD, and Refit MELDNa scores was between the Child-Pugh score and Refit MELD in patients with persistent ascites (P=0.039).

Conclusions

Refit MELD and Refit MELDNa exhibited good predictability for 3-month mortality in patients with cirrhosis and ascites. However, Refit MELDNa was not found to be a better predictor than Refit MELD, despite the known relationship between hyponatremia and mortality in cirrhotic patients with ascites.

Citations

Citations to this article as recorded by  Crossref logo
  • Multimodal ultrasound: a non-invasive method for identifying dedifferentiation of papillary thyroid carcinoma during active surveillance
    Qian-Yi Dou, Huan-Ling Guo, Wan-Bing Qiu, Ming Xu, Shu-Ling Chen, Xiao-Er Zhang, Xiao-Yan Xie, Jin-Yu Liang
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • The diagnostic accuracy of ascitic calprotectin for the early diagnosis of spontaneous bacterial peritonitis: systematic review and meta-analysis
    Alexandros Hadjivasilis, Alexander Tzanis, Kalliopi J. Ioakim, Ioanna Poupoutsi, Aris P. Agouridis, Panayiotis Kouis
    European Journal of Gastroenterology & Hepatology.2021; 33(3): 312.     CrossRef
  • Influence of preoperative sodium concentration on outcome of patients with hepatitis B virus cirrhosis after liver transplantation
    Peijie Wang, Gang Huang, Ngalei Tam, Chenglin Wu, Shunjun Fu, Bridget P. Hughes, Linwei Wu, Xiaoshun He
    European Journal of Gastroenterology & Hepatology.2016; 28(10): 1210.     CrossRef
  • 9,891 View
  • 51 Download
  • 6 Web of Science
  • Crossref
The Korean Journal of Hepatology Elsewhere
The use of vaptan in hyponatremic patients with liver cirrhosis
Won Hyeok Choe
Korean J Hepatol 2011;17(4):335-337.
Published online December 26, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.4.335

Citations

Citations to this article as recorded by  Crossref logo
  • Tolvaptan versus other interventions for hyponatraemia in people with cirrhosis
    K N Anila, Nair S Saraswathy, Zubair U Mohamed, Christi Titus Varghese, S T Binoj, Unnikrishnan Gopalakrishnan, Dinesh Balakrishnan, Arun Valsan, Surendran Sudhindran
    Cochrane Database of Systematic Reviews.2025;[Epub]     CrossRef
  • 11,213 View
  • 53 Download
  • Crossref